We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

TC Biopharm

Status: Stretch

Mar 21st 2016 - Jul 9th 2016

TC BioPharm (TCB) has created a clinical therapy called ImmuniCell. This therapy is designed to use the body's own immune system to fight cancerous tumours and viral infections. TCB will use a portion of the proceeds raised to complete its Phase IIa trials

 

read more read less
Log in to view amount pledged

    Log in to view target

    £8,001,367
    pre-money valuation

    12.25%
    equity available

    58
    investors

    £20,546
    pledge per investor

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    11 Mar 24 Syndicate Room £1,191,687 / 107%

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £8,001,367
    pre-money valuation

    12.25%
    equity available

    58
    investors

    £20,546
    pledge per investor

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    11 Mar 24 Syndicate Room £1,191,687 / 107%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph